English | Español

Johnson & Johnson
Press release submission | May 21, 2021

RYBREVANT™ (amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Press release submission | Dec 20, 2019

JOHNSON & JOHNSON: Acquires TARIS Biomedical with Focus on Transforming the Treatment of Bladder Cancer

Press release submission | Jun 14, 2019

JOHNSON & JOHNSON: Janssen reports top-line Phase 3 results for TREMFYA® (guselkumab) in adults with active psoriatic arthritis

Trending
+ Technology/Innovation
Patient Daily News Service | Oct 9, 2025

Babylon Health collapse raises questions about AI claims across industries
Patient Daily | Oct 9, 2025

Medfluence Advisors Marketing Expert: 'The conversations leading into AAO-HNSF are shaping how ENT practices approach growth and engagement'
Patient Daily | Oct 9, 2025

AI takes center stage at ASCENT ENT conference, reshaping marketing and operations
+ Pharmaceuticals
Patient Daily | Oct 8, 2025

American Lung Association launches campaign urging vaccinations against seasonal flu and respiratory illnesses